Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity

Early responders (15% or more weight loss after 24 weeks) to the higher dose of Wegovy ® (semaglutide 7.2 mg) achieved on average 27.7% mean weight loss at week 72 in the STEP UP trial1 Participants treated with the higher dose of Wegovy ® reached weight loss goals faster as compared to semaglutide 2.4 mg1 The majority of the weight loss comes from losing body fat: 84% of weight loss with Wegovy ® (semaglutide 2.4 and 7.2 mg) can be attributed to reductions in fat mass, while preserving muscle function and improving muscle health2 Bagsværd, Denmark, 12 May 2026 – Novo Nordisk is presenting a new sub-analysis from the large clinical trial STEP UP at the European Congress on Obesity (ECO) on 12-15 May in Istanbul, Türkiye, showing that the higher dose of the weight loss drug Wegovy ® is highly effective at helping people with obesity lose significant amounts of weight regardless of how quickly their body responds to the treatment1. Moreover, a separate STEP UP sub-analysis presented at ECO shows that most of the weight loss with Wegovy ® was coming from body fat, and most of the muscle mass was kept2.